Back to Cell Types

KYSE-450Homo sapiens (Human)Cancer cell line

Also known as: Kyse450, KYSE450, KYSE 450

🤖 AI SummaryBased on 11 publications

Quick Overview

KYSE-450 is a human esophageal squamous cell carcinoma cell line used in cancer research.

Detailed Summary

KYSE-450 is a human esophageal squamous cell carcinoma cell line derived from surgically resected tumors. It is commonly used in research to study the molecular mechanisms of cancer progression and drug sensitivity. The cell line has been characterized for genetic and epigenetic alterations, including homozygous deletions and promoter methylation of genes such as LRP1B and PARD3. These alterations are associated with tumor suppressor gene inactivation and may contribute to cancer development. KYSE-450 is part of a panel of cell lines used in high-throughput genomic and transcriptomic studies to identify potential therapeutic targets and biomarkers for cancer treatment.

Research Applications

Cancer genomicsDrug sensitivity profilingEpigenetic regulation studiesTumor suppressor gene analysis

Key Characteristics

Homozygous deletions in LRP1BPromoter methylation of PARD3Used in high-throughput genomic screens

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1353
Species	Homo sapiens (Human)
Tissue Source	Esophagus[UBERON:UBERON_0001043]

Donor Information

Age	59
Age Category	Adult
Sex	Male
Race	asian

Disease Information

Disease	Squamous cell carcinoma of the esophagus
Lineage	Esophagus/Stomach
Subtype	Esophageal Squamous Cell Carcinoma
OncoTree Code	ESCC

DepMap Information

Source Type	DSMZ
Source ID	ACH-000865_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Glu339Ter (c.1015G>T)	Heterozygous	-	Unknown, Unknown, PubMed=8575860
MutationSimple	TP53	p.His179Arg (c.536A>G)	Unspecified	-	PubMed=35297208

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11,12

D13S317

11

D16S539

9

D18S51

13

D19S433

13,15

D21S11

30

D2S1338

19,23

D3S1358

18

D5S818

10,13

D7S820

11,12

D8S1179

10

FGA

24

Penta D

9,10

Penta E

11,16

TH01

8,9

TPOX

8

vWA

14

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Hypermethylation of MAPK13 promoter in oesophageal squamous cell carcinoma is associated with loss of p38delta MAPK expression.

O'Callaghan C., Fanning L.J., Barry O.P.

Cancers (Basel) 7:2124-2133(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Radiation sensitivities of 31 human oesophageal squamous cell carcinoma cell lines.

Shimada Y., Inazawa J., Imai T.

Int. J. Exp. Pathol. 86:231-240(2005).

Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma.

Imamura M., Amagasa T., Gray J.W., Hirohashi S., Inazawa J.

Cancer Res. 64:3741-3747(2004).

Nonrandom chromosomal imbalances in esophageal squamous cell carcinoma cell lines: possible involvement of the ATF3 and CENPF genes in the 1q32 amplicon.

Yang Z.-Q., Imamura M., Nakamura Y., Amagasa T., Inazawa J.

Jpn. J. Cancer Res. 91:1126-1133(2000).

Multiple types of aberrations in the p16 (INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines.

Tanaka H., Shimada Y., Imamura M., Shibagaki I., Ishizaki K.

Int. J. Cancer 70:437-442(1997).

Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors.

Ishizaki K.

Int. J. Cancer 65:372-376(1996).

Analysis of gene amplification and overexpression in human esophageal-carcinoma cell lines.

Fukumoto M.

Int. J. Cancer 58:291-297(1994).

Characterization of 21 newly established esophageal cancer cell lines.

Shimada Y., Imamura M., Wagata T., Yamaguchi N., Tobe T.

Cancer 69:277-284(1992).